Spirit Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a form-specific veterinary active pharmaceutical ingredient platform covering six release designations: Spirit VT-101 for tablet compression, Spirit VC-101 for capsule filling, Spirit VP-101 for oral powders and granules, Spirit VX-101 for medicated feed premix, Spirit VS-101 for solution compounding, and Spirit VI-101 for injectable solution preparation. These designations represent the same chemical entity under different physical, microbial, and packaging controls and are not separate salts or polymorphs unless the approved registration dossier explicitly specifies a salt form. Manufacture is conducted under EU GMP Part II for active substances used in veterinary medicinal products. Release documentation supports EU Regulation 2019/6 and relevant national dossiers. The product is not sterile and is not a finished dosage form; terminal sterilisation, aseptic filtration, or preservative addition remains the responsibility of the marketing authorisation holder.

Every batch is released against a certificate of analysis covering assay, related substances, residual solvents, loss on drying, residue on ignition, and grade-specific physical or microbial properties. The assay acceptance envelope is 98.0–102.0% on dried basis. Total related substances are controlled at ≤0.5%, and any unspecified impurity is controlled at ≤0.10%. Residual solvents are controlled according to ICH Q3C; Class 1 solvents are absent at the method limit, and Class 2 solvents are below the permitted daily exposure calculated for the target species. Loss on drying is ≤0.5% for Spirit VI-101 and ≤1.0% for the oral, premix, and solution designations. Residue on ignition is ≤0.1%. Heavy metals are controlled at ≤10 ppm only where the relevant active substance monograph retains the compendial limit test; otherwise the elemental impurity risk assessment is documented under ICH Q3D principles.

How Does the Spirit Platform Differ from Single-Grade and Technical-Grade Materials?

Technical-grade feed additives and non-GMP bulk actives are not interchangeable with Spirit Veterinary Grade API. The platform is released against pharmacopoeial impurity and residual solvent limits; technical-grade materials often carry only assay, moisture, and heavy metal data and may contain process-related impurities above the safety thresholds applied to veterinary medicinal products. Documentation includes an active substance master file or veterinary master file, zone-specific stability data, and batch-to-batch physical property data required for downstream process validation. In contrast to a single-grade veterinary API, the form-specific designations avoid site-level milling, sieving, and reconditioning operations that can introduce cross-contamination risk and shift particle size distribution.

Compared with a human-grade API of the same chemical entity, Spirit Veterinary Grade API may use the same compendial assay and impurity methods, but it adds acceptance criteria for target-animal feed carryover, dusting potential, and packaging suitability for veterinary clinics and feed mills. Human-grade API documentation does not normally address withdrawal periods, milk or egg residues, or compatibility with medicated feed carriers. Compared with a finished veterinary premix or oral powder, the API contains no excipients, carriers, or preservatives; blend uniformity and final dose accuracy must therefore be demonstrated by the marketing authorisation holder using the form-specific grade.

Form-Specific Grade Designations and the Downstream Processing Window

The table below lists the model designations and the primary downstream controls associated with each dosage-form route. The physical specifications are not target values for all active moieties; they are the release envelope for a neutral, crystalline active substance with adequate flow. For low-melting-point or hygroscopic actives, the envelope is adjusted in the registration commitment.

Spirit VI-101 is released under more restrictive particulate and microbial controls than the oral designations. Total aerobic microbial count is ≤10¹ CFU/g, and combined yeast and mould count is ≤10¹ CFU/g. The material is not sterile, but bioburden reduction, moisture control, and particle size control support subsequent terminal sterilisation or aseptic filtration through a 0.22 µm membrane. Sub-visible particulate burden is assessed after reconstitution in particle-free water using light obscuration; the acceptance limit is applied to the finished solution rather than to the dry powder alone. In production-scale filtration studies, the filtration rate is influenced by sub-10 µm particle fines and by solution viscosity; dissolution time and clarity are therefore reported for each batch. Storage of opened containers at relative humidity above 60% without desiccant is not recommended because moisture uptake can increase aggregation and shift reconstitution time.

When Premix Carriers and Granule Density Control Feed-Dose Variability

For Spirit VX-101 in medicated feed premix, the largest processing risk is segregation during blending and pneumatic transfer. Uniformity of content is assessed after blending at the intended inclusion rate; the batch is released for commercial use only when the relative standard deviation of active content is ≤5.0% across sampling points. Bulk density and tapped density are controlled because a density mismatch between API and carrier above approximately 0.20 g/cm³ can produce stratification in a double-cone blender. The carrier should be selected with a moisture content below 12% and a pH below 8.0 to avoid hydrolysis of the active moiety. Amine-based carriers or mineral carriers containing free alkaline earth oxides are incompatible with the product and may produce degradation-related impurities above the release limit.

Direct-compression tablet grade Spirit VT-101 is specified with a D₅₀ in the range 50–150 µm and a D₉₀ ≤150 µm. Tablet formulations should be designed to a target compression force that yields hardness in the range 50–120 N and friability ≤1.0% as measured by Ph. Eur. 2.9.7; the exact force depends on excipient choice and tablet geometry. In capsule filling, Spirit VC-101 is specified with a D₉₀ ≤100 µm to maintain uniformity of weight during high-speed encapsulation. Powder flow is characterised by Hausner ratio; a Hausner ratio above 1.30 indicates poor flow and may require the addition of glidant.

For wet granulation of Spirit VP-101, the liquid-to-solid ratio is selected to achieve a wet mass consistency with impeller torque between 20 N·m and 40 N·m on a 25 L high-shear granulator. Endpoint is determined by impeller power consumption rather than time alone. Drying is performed with inlet air temperature not exceeding 60 °C to avoid thermal degradation. The dried granules are milled through a 1.0 mm screen and blended with extragranular disintegrant. The final granule fraction between 0.125 mm and 1.0 mm reduces dusting during transfer and supports reproducible die filling.

Release Specification Envelope and Residual Solvent Boundaries

Method suitability is verified for each grade because finished veterinary matrices can interfere with direct API methods. Feed premix matrices containing alfalfa meal, mineral oil, or molasses require extraction cleanup before HPLC assay; the validated method should demonstrate recovery between 98.0% and 102.0% in the presence of matrix components. Stability-indicating methods separate the active peak from oxidative and hydrolytic degradation products; forced degradation studies include acid, base, peroxide, thermal, and photolytic conditions. Where the product is intended for food-producing species, residue depletion and withdrawal period data are supplied in the veterinary medicine dossier, not in the API certificate of analysis.

Stability data are generated using ICH Q1A conditions: long-term 25 °C/60% RH, intermediate 30 °C/65% RH, and accelerated 40 °C/75% RH. The retest period is assigned from long-term data and may be extended with ongoing stability batches. Packaging is high-density polyethylene with a heat-sealed aluminium foil overwrap; the double-bag configuration reduces moisture ingress during storage. For moisture-sensitive designations, desiccant is placed between the inner and outer bags. The container closure system is qualified for transport under tropical conditions because field failures in veterinary distribution often occur at humidity above 75% RH.

In dissolution testing, the difference between tablet and capsule grades is most visible. Spirit VT-101 is controlled for particle size and flow so that finished tablets meet a typical dissolution criterion of Q=80% at 30 minutes for a highly soluble active moiety in 0.1 N HCl. For poorly soluble actives, the particle size of Spirit VC-101 or Spirit VS-101 is reduced or a specified polymorph is selected; the dissolution method and acceptance criterion must be established in the finished product dossier. Bioequivalence or target animal efficacy data are not part of the API release and must be generated by the applicant.

Cleaning validation for the multi-product facility follows EU GMP Part II and includes swab and rinse limits derived from the permitted daily exposure of the most potent veterinary active. Carryover of a previous product into Spirit Veterinary Grade API is controlled below 10 ppm to maintain the impurity profile. Cross-contamination risk is further reduced by dedicated sieving and milling capability for each physical grade and by verification of retained solvent levels after cleaning.

For solution-grade Spirit VS-101, clarity after reconstitution is assessed using a validated nephelometric method; the acceptance value is ≤3 NTU for a 10% w/v solution in purified water at 25 °C. This criterion is not applied to Spirit VI-101 injection grade, where sub-visible particle counts are controlled instead. The oral powder and granule grades are sieved to pass 1.0 mm but retain a particle fraction above 0.125 mm to reduce dusting during feed mixing; this range may be adjusted following site-specific occupational exposure monitoring. The solution and parenteral grades are not intended for direct administration without dilution or vehicle preparation.